POSSIBILITIES OF USING CERVICON-DIM IN PATIENTS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA
N.V. Zarochentseva, L.K. Jijihia
For quotation:
Zarochentseva N.V., Dzhidzhikhia L.K. Possibilities of using the drug Cervicon-DIM in patients with cervical intraepithelial neoplasia. Questions of practical colposcopy. Genital infections. 2022; (3): 40–46.
DOI: 10.46393/27826392_2022_3_40
Annotation:
Cervical cancer (CC) is one of the most common forms of cancer in Russia and most countries of the world. Cervical intraepithelial neoplasia (CIN) precedes the development of cervical cancer. Human papillomavirus (HPV) is the main etiological factor in the development of precancerous changes in the cervix. The management and treatment tactics for patients with CIN of varying severity have been determined. However, despite this, further progression of the process is observed. Therefore, the search for conservative treatment methods for CIN remains relevant.
Purpose of the review: to present our own experience of using a drug containing 3,3’-diindolylmethane (Cervicon®-DIM) in patients with CIN both at the stage of preparation for cervical biopsy and for treatment.
Material and methods. 52 patients with HPV-associated low- and moderate-grade cervical intraepithelial lesions (CIN I–II) were examined and treated with Cervicon®-DIM containing 3,3’-diindolylmethane at the stage of preparation for cervical biopsy, as well as during treatment. During the initial diagnosis and monitoring the results of therapy, colposcopy, cytological examination of the cervix, PCR of high carcinogenic risk HPV (HCR) and histological examination of biopsy samples of cervical areas were performed.
Results. Results of treatment of patients with CIN I–II using a drug containing 3,3'-diindolylmethane (Cervicon®-DIM) in the form of vaginal suppositories (100 mg twice a day for 60 days in preparation for cervical biopsy with continued therapy within 4 months after receiving the histological result) showed clinical (normalization of the colposcopic picture), cytological (confirmed absence of LSIL/CIN I and HSIL/CIN II) and microbiological (negative result for HPV HCR) effectiveness with satisfactory tolerability of the drug in 78.6% women.
Conclusion. The results obtained in the treatment of patients with HPV-associated low and moderate cervical intraepithelial lesions using a drug containing 3,3'-diindolylmethane (Cervicon®-DIM) can be considered satisfactory. There was a significant reduction in the area of mild and severe cervical lesions when using Cervicon®-DIM immediately before cervical biopsy and excisional manipulation of the cervix.
Journal “Issues of practical colposcopy. Genital infections" No. 3_2022
https://drive.google.com/file/d/1OzJMdQ-VCgKHCt0vHydJfiqs8MGZ0xq9/view
N.V. Zarochentseva, L.K. Jijihia
For quotation:
Zarochentseva N.V., Dzhidzhikhia L.K. Possibilities of using the drug Cervicon-DIM in patients with cervical intraepithelial neoplasia. Questions of practical colposcopy. Genital infections. 2022; (3): 40–46.
DOI: 10.46393/27826392_2022_3_40
Annotation:
Cervical cancer (CC) is one of the most common forms of cancer in Russia and most countries of the world. Cervical intraepithelial neoplasia (CIN) precedes the development of cervical cancer. Human papillomavirus (HPV) is the main etiological factor in the development of precancerous changes in the cervix. The management and treatment tactics for patients with CIN of varying severity have been determined. However, despite this, further progression of the process is observed. Therefore, the search for conservative treatment methods for CIN remains relevant.
Purpose of the review: to present our own experience of using a drug containing 3,3’-diindolylmethane (Cervicon®-DIM) in patients with CIN both at the stage of preparation for cervical biopsy and for treatment.
Material and methods. 52 patients with HPV-associated low- and moderate-grade cervical intraepithelial lesions (CIN I–II) were examined and treated with Cervicon®-DIM containing 3,3’-diindolylmethane at the stage of preparation for cervical biopsy, as well as during treatment. During the initial diagnosis and monitoring the results of therapy, colposcopy, cytological examination of the cervix, PCR of high carcinogenic risk HPV (HCR) and histological examination of biopsy samples of cervical areas were performed.
Results. Results of treatment of patients with CIN I–II using a drug containing 3,3'-diindolylmethane (Cervicon®-DIM) in the form of vaginal suppositories (100 mg twice a day for 60 days in preparation for cervical biopsy with continued therapy within 4 months after receiving the histological result) showed clinical (normalization of the colposcopic picture), cytological (confirmed absence of LSIL/CIN I and HSIL/CIN II) and microbiological (negative result for HPV HCR) effectiveness with satisfactory tolerability of the drug in 78.6% women.
Conclusion. The results obtained in the treatment of patients with HPV-associated low and moderate cervical intraepithelial lesions using a drug containing 3,3'-diindolylmethane (Cervicon®-DIM) can be considered satisfactory. There was a significant reduction in the area of mild and severe cervical lesions when using Cervicon®-DIM immediately before cervical biopsy and excisional manipulation of the cervix.
Journal “Issues of practical colposcopy. Genital infections" No. 3_2022
https://drive.google.com/file/d/1OzJMdQ-VCgKHCt0vHydJfiqs8MGZ0xq9/view
